Notably, high MYC and CCND1 expression also correlates with poor relapse-free survival in BC patients treated with endocrine therapies (though it should be noted that the results for CCND1 are not as statistically significant as those for MYC, Figure S3A,B). The gene discussed is CCND1; the disease is breast cancer.